1477949-42-0 Usage
Description
CAY10683 (SantacruzaMate A) is a naturally occurring compound derived from the Panamanian marine cyanobacterium Symploca sp. It is a potent and selective inhibitor of histone deacetylases (HDACs), particularly HDAC2, with an IC50 value of 0.119 nM for HDAC2 and 434 nM for HDAC6. SantacruzaMate A has been identified as a potential therapeutic agent for breast cancer and has demonstrated the ability to induce apoptosis and cancer cell death when combined with other HDAC1 inhibitors. Additionally, it has shown promise in attenuating Aβ fragment-induced toxicity in PC12 cells by enhancing ER stress tolerance and ameliorating Alzheimer's disease-like pathology in mouse models.
Uses
Used in Pharmaceutical Industry:
CAY10683 (SantacruzaMate A) is used as a targeted therapy agent for breast cancer in women due to its selective inhibition of HDAC2, which plays a role in the development and progression of the disease.
Used in Anticancer Applications:
CAY10683 (SantacruzaMate A) is used as an anticancer agent for breast cancer treatment, as it induces apoptosis and cancer cell death when combined with other HDAC1 inhibitors.
Used in Neurodegenerative Disease Research:
CAY10683 (SantacruzaMate A) is used as a potential therapeutic agent for Alzheimer's disease, as it has been shown to attenuate Aβ fragment-induced toxicity in PC12 cells and ameliorate Alzheimer's disease-like pathology in mouse models.
Used in Drug Delivery Systems:
While not explicitly mentioned in the provided materials, given the potential therapeutic applications of CAY10683 (SantacruzaMate A), it could be used in the development of novel drug delivery systems to enhance its bioavailability, delivery, and therapeutic outcomes in various medical applications.
References
1) Pavlik?et al.?(2013),?Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.; J. Nat. Prod.,?76?2026
2) Zhou?et al.?(2018),?Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21Waf1/Cip1 and p19INK4d upregulation in hepatocellular carcinoma; Cell Prolif.,?51(3)?e12447
3) Damaskos?et al.?(2017),?Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer;?Anticancer Res.,?37?35
4) Chen?et al.?(2019),?Santacruzamate A Ameliorates AD-Like Pathology by Enhancing ER Stress Tolerance Through Regulating the Functions of KDELR and Mia40-ALR in vivo and in vitro;?Front. Cell. Neurosci.,?13?61
Check Digit Verification of cas no
The CAS Registry Mumber 1477949-42-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,7,7,9,4 and 9 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1477949-42:
(9*1)+(8*4)+(7*7)+(6*7)+(5*9)+(4*4)+(3*9)+(2*4)+(1*2)=230
230 % 10 = 0
So 1477949-42-0 is a valid CAS Registry Number.
1477949-42-0Relevant articles and documents
Synthesis and biological evaluation of Santacruzamate-A based analogues
Randino, Rosario,Gazzerro, Patrizia,Mazitschek, Ralph,Rodriquez, Manuela
, p. 6486 - 6491 (2017)
Several derivatives of Santacruzamate-A, a natural product that is structurally related to SAHA, were synthesized to explore the potential of carbamates and oxalylamides as novel biasing element for targeting the catalytic site of zinc-dependent histone deacetylases (HDACs). An additional class of Santacruzamate-A derivatives was synthesized to investigate the influence of the cap group and the linker element on HDAC inhibitory activity. All compounds were evaluated in dose response for their in vitro cytotoxic activity in MTT assay in HCT116 cells. HDAC inhibitory activity was evaluated in vitro by western blot analysis for histone hyperacetylation assay and biochemically for representative human HDACs isoforms. Two novel compounds were identified to exhibit potent time dependent anti proliferative activity. However, unlike hydroxamic acid analogues, the tested Santacruzamate-A derivatives showed no noticeable HDAC inhibitory activity. The ethylcarbamate moiety as unusual zinc-binding group displayed no ability to coordinate the zinc ion and thus, presumably, was not able to reproduce known inhibitor-substrate zinc-binding group interactions with the HDAC catalytic site. This study confirmed that the accommodation of the zinc-binding group is deeply critical of the positioning of the linker and the projection of the cap group toward the different surface pockets of the enzyme.
SANTACRUZAMATE A COMPOSITIONS AND ANALOGS AND METHODS OF USE
-
Page/Page column 33, (2014/02/16)
The compositions and methods described herein relate generally to Santacruzamate A compositions and analogs, which, among other features, are useful as histone deacetylase (HDAC) inhibitors.
